An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, investigators ...

In a Johns Hopkins Children’s Center study, the addition of navitoclax to the standard TB treatment significantly increased ...

TB Alliance's third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving affordability and accessTB Alliance applauds a new milestone in the fight ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, Johns Hopkins ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, Johns Hopkins ...

In a Johns Hopkins Children’s Center study, the addition of navitoclax to the standard TB treatment significantly increased apoptosis (shown in red) in several lung cell populations including ...

Another concern Hewison points to is that, during the course of treatment, "TB often naturally develops resistance to drugs." When this occurs and the initial rounds of antibiotics stop working ...

Berhampur: The state govt has rolled out BPaLM, a shorter duration new treatment regimen for multi-drug resistant tuberculosis (MDR-TB) patients. The 26-week long BPaLM treatment regimen was ...